MicroRNA-26a-mediated regulation of interleukin-2 expression in transformed avian lymphocyte lines
© Xu et al; licensee BioMed Central Ltd. 2010
Received: 22 January 2010
Accepted: 4 May 2010
Published: 4 May 2010
Micro(mi)RNAs are a class of small non-coding RNAs that play critical roles in the induction of various cancers, including lymphomas induced by oncogenic viruses. While some of the miRNAs are oncogenic, miRNAs such as miR-26a are consistently downregulated in a number of cancers, demonstrating their potential tumor suppressor functions. Global miRNA expression profiles of a number of virus-transformed avian lymphoma cell lines have shown downregulation of gga-miR-26a expression, irrespective of molecular mechanisms of transformation or the viral aetiology. The neoplastic transformation of lymphocytes by many viruses accompanies high levels of proliferative responses, mostly mediated through cytokines such as IL-2. Chicken IL-2 can modulate T-cell proliferation and cytotoxicity in vitro and in vivo and dysregulation of IL-2 expression is observed in diseases such as leukaemia.
The expression levels of gga-miR-26a in chicken lymphoma cells transformed by 3 distinct avian oncogenic viruses, viz Marek's disease virus (MDV), avian leukosis virus (ALV) and Reticuloendotheliosis virus (REV) were consistently downregulated compared to the levels in the normal lymphocytes. This downregulation of miR-26a regardless of the viral etiology and molecular mechanisms of transformation was consistent with the tumor suppressor role of this miRNA. Notwithstanding this well-established role in cancer, we demonstrate the additional role of this miRNA in directly targeting chicken IL-2 through reporter and biochemical assays. The downregulation of miR-26a can relieve the suppressive effect of this miRNA on IL-2 expression.
We show that miR-26a is globally downregulated in a number of avian lymphoma cells irrespective of the mechanisms of transformation, reiterating the highly conserved tumor suppressor function of this miRNA. However, with the potential for directly targeting chicken IL-2, the downregulation of miR-26a in these tumor cells could relieve the inhibitory effect on IL-2 expression assisting in the proliferative features of the transformed lymphocyte lines.
Micro(mi)RNAs are a large class of ~22-nucleotide non-coding RNA molecules that participate a major part in the regulation of gene expression in majority of the eukaryotes. Increasingly, they have been shown to play significant roles in a variety of cancers, in particular of those involving different blood cells . Marek's disease (MD), a naturally occurring CD4+ T-cell lymphoma in chickens induced by Marek's disease virus (MDV), is considered to be a very good model for herpesvirus-induced rapid-onset T-cell lymphomas . Recent studies on the miRNA expression profiles of a number of MDV-transformed chicken lymphoid cell lines have shown significant alterations in the expression of several host miRNAs compared to the normal chicken lymphocytes . One of the miRNAs that was consistently downregulated in a number of MDV-transformed chicken lymphoid cell lines is gga-miR-26a . Suppression of miR-26a has been demonstrated in a variety of human cancers also [4–6] suggesting that miR-26a has potential tumour suppression functions, and its downregulation could be essential for transformation. This notion is supported from the roles of miR-26a in p53 tumour suppressor network , as well as in the regulation of transformation-related targets such as cyclin D2, SMAD1, EZH2 and PTEN [8, 9].
Antigen-specific T cell proliferation and immunological responses are dependent on the expression of several cytokine genes such as interleukin-2 (IL-2). IL-2 plays an important role in the development, differentiation and homeostasis of T cells, and IL-2 expression is dysregulated in diseases such as leukaemia, autoimmunity and pathogenesis of viral diseases , including MD . As in mammals, the chicken IL-2 can modulate T-cell proliferation and cytotoxicity in vitro and in vivo . The mechanisms of transcriptional regulation of IL-2 promoters through activating transcription factors such as NFκB or AP-1 have been extensively studied . Negative regulation of IL-2 expression is also important both for maintaining the gene in an inactive state in resting cells and for repressing the gene after the activation. Compared to the studies on transactivation, the mechanisms involved in the negative regulation of IL-2 gene expression are less well studied. Although the roles of co-repressors and histone deacetylases in the transcriptional repression of IL-2 has been demonstrated , it is also becoming clear that a number of miRNAs are also involved in shaping of the immune responses [15, 16] at least in part through the regulation of cytokine genes . For example, miR-146a has been shown to modulate the adaptive immune responses by regulating the IL-2 expression in human T lymphocytes . However, chicken IL-2 is not a predicted target of gga-miR-146a http://www.ebi.ac.uk/enright-srv/microcosm/htdocs/targets/. Although miR-26a has not been implicated in the regulation of IL-2, we examined whether miR-26a downregulation in MDV-transformed chicken lymphoma cell lines do affect IL-2 expression. We present the data suggesting that chicken IL-2 is a direct target of miR-26a, and its downregulation could affect IL-2 expression and signalling pathways in these transformed cells.
Transformed chicken cell lines show downregulation of miR-26a
Targeting of chicken IL-2 by miR-26a in reporter assays
Downregulation of IL-2 expression by miR-26a
Levels of miR-26a affect IL-2 expression
We also examined how the changes in the expression of miR-26a affected the IL-2 expression. MiR-26a expression vector and control vector were respectively co-transfected with pcDNA-IL-2-3HA-3'UTR into DF-1, and then cells were examined by western blot analysis (Fig. 4c). It showed that the IL-2 expression level was reduced by more than 30% in the presence of miR-26a compared to the levels in cells transfected with pEF6-miR-26a (-) control vector. In contrast, the IL-2 expression level was increased by more than 140% when the miR-26a levels were silenced using the anti-miR-26a compared to the anti-miRNA control (Fig.4d).
Over the last 5 years, miRNAs have emerged as major regulators of gene expression and cancer pathogenesis. Nearly all of the tumours, irrespective of the cell type or etiology, have shown globally abnormal miRNA expression patterns and miRNA profiles of tumours have given valuable insights into downstream pathways of oncogenesis [19–25]. We have previously demonstrated that miR-26a is downregulated in seven independently-derived MDV-transformed lymphoblastoid T cell lines . Here, we show that such downregulation of miR-26a occur in lymphoid cell lines transformed by ALV and REV also, suggesting that miR-26a-mediated modulation of gene expression is probably crucial for lymphocyte transformation, irrespective of the viral etiology. The identification of some of the validated targets of miR-26a including EZH2 , SMAD1 , PTEN  provides intriguing link to the oncogenic pathways. Loss of expression of miR-26a also occurs in some of the human tumours such as thyroid anaplastic carcinoma  and Burkitt's lymphoma  reiterating the role of miR-26a as a tumour suppressor, the expression of which can protect from the disease progression in cancer models [5, 27].
In this study we demonstrate that, in addition to its potential role as a tumour suppressor, miR-26a also functions as a modulator of IL-2 expression. IL-2 is produced mainly by activated T helper CD4+ lymphocytes and is one of critical cytokines that control the proliferation and clonal expansion of transformed lymphoma cells . In MDV-transformed tumour cells, MDV-encoded oncoprotein Meq is thought to play a direct role in the upregulation of IL-2 expression by binding to the IL-2 promoter . Our study shows that the downregulation of miR-26a is another global pathway for the increased IL-2 expression in the lymphoma cell lines transformed by the avian oncogenic viruses MDV, ALV and REV.
Our study does not examine the molecular mechanisms of downregulation of miR-26a. Some of the previous studies have shown the role of oncogenes such as c-myc in regulating miR-26a expression [4, 30, 31] and the altered expression of miR-26a in HP45 could be related to the increased c-myc expression. Similarly, the reduced expression of miR-26a in AVOL1 and AVOL2 cell lines may also be mediated by the v-rel. In MD tumour cell lines, the MDV-encoded oncoprotein MEQ is thought to be the primary determinant of transformation . Presence of a putative MEQ-binding sequence ACACA at -650 nucleotide position would suggest a role of MEQ in modulating the miR-26a expression, although further studies are required validate this.
In summary, we show that miR-26a is globally downregulated in a number of avian lymphoma cells transformed by different oncogenic viruses that use multiple pathways for inducing transformation. In addition to its role as a global tumor suppressor miRNA, we also provide data to show that chicken IL-2 is a direct target for miR-26a. Our study suggests that the suppression of miR-26a could potentially relieve the inhibitory effect on IL-2 expression and could contribute to the proliferative features of the transformed lymphocyte lines.
Analysis of miRNA expression
Details of the microarray experiments carried out using small RNA samples prepared from transformed lymphoblastoid cell lines, normal splenocytes were labelled with either Cy3 or Cy5 197 dyes using the Array 900microRNA RT kit from Genisphere (Hatfield, PA) and hybridized to μRNA microarray have been described . For Northern blot analysis, 20 μg of total RNA extracted from cultured cells by using TRIzol reagent (Invitrogen) were resolved on a 15% polyacrylamide urea gel and blotted onto a GeneScreen Plus membrane (Perkin-Elmer). DNA oligonucleotide with the complementary sequence to miR-26a was end labelled with [γ-32P] ATP by T4 polynucleotide kinase (New England Biolabs). Hybridization and autoradiography were carried out using standard methods as previously described .
Construction of reporter vectors
The region containing the IL-2 3'UTR, amplified from chicken spleen genomic DNA by PCR using the forward primer (5'-CTCGAGGCAACTAATCATTTTTATTTTAC TGC-3') and the reverse primer (5'-CATATATTACTGAAATTTATTAAATG-3'), was cloned initially into pGEM-T Easy vector (Promega). The IL-2 3' UTR mutant with three nucleotides altered in seed sequence was constructed using the Quikchange™ site-directed mutagenesis kit (Stratagene CA) using the forward primer (5'-CTGCATGGACCTAACATTCGATGATCATTCAGTTTAATAGG TTAAACTGCAATTGA-3') and reverse primer (5' TCAATTGCAGTTTAACCTAT TAAACTGAATGATCATCGAATGTTAGGTCCATGCAG-3'). After confirming the sequence of the wild type and mutant regions of the IL-2 3'UTR, these were cloned downstream of the Renilla luciferase gene through the Not I - Xho I site in psiCheck-2 vector (Promega) to generate psiCheck2-IL-2 3' UTR-Wt and psiCheck2-IL-2 3' UTR-Mu reporter constructs.
Construction of miR-26a expression vectors
For the construction of gga-miR-26a expression plasmids, the miR-26a primary gene together with ~200-bp flanking sequences were amplified from chicken genomic DNA using primer pairs (5'-ATGTTCTTTAATGTCGGGAGC-3') and (5'-AAAGAATTCTGCCCGTGAC-3'), and cloned into pEF6-V5/His TOPO vector (Invitrogen) under control of EF1α promoter vector. Another construct where the sequence was cloned in the reverse orientation was used as the negative control.
Construction of chicken IL-2 expression vectors
As we did not have the specific antibodies that detect the chicken IL-2, we constructed IL-2 expression vector with a C-terminal HA tag and the 3'UTR. For this, the IL-2 gene, amplified by PCR with the forward primer (5'-AAGCTTGCCACCAT GATGTGCAAAGTACTGATC-3') that included the Kozak sequence and Hind III site and reverse primer (5'-CTCGAGTTAAGCGTAATCTGGAACATCGTAT GGGTATGCCATTTTTTGCAGATATCTCAC-3') carrying the haemagglutinin (HA) tag sequence and Xho I site, was initially cloned into pGEM-T Easy vector. The IL-2 gene and 3'UTR regions were ligated by Xho I and Not I and cloned into Hind III- Not I site in pcDNA3.1 vector to construct the IL-2 expression vector with the C-terminal HA tag and the 3' UTR.
Cell culture, reporter assays and miRNA expression
MDV-transformed lymphoid cell lines MSB-1, 226S, 265L and 273S, avian leukosis virus (ALV)-transformed cell line HP45, and reticuloendotheliosis virus (REV)-transformed cell lines AVOL1 and AVOL2 have been described . Chicken embryo fibroblast cell line DF-1  was used for reporter assays and expression studies. The transfection of DF-1 cells was carried out with Lipofectamine 2000 (Invitrogen) as per manufacturer's protocols. Approximately 5 × 104 DF-1 cells were seeded in each well of a 96-well plate. Purified DNA (100 nanograms) of the reporter vectors were transfected into DF-1 cells in triplicates and luciferase assay was performed using the Dual Glo Luciferase Assay System (Promega) 24-hour after transfection. The relative expression levels were calculated as a ratio of the target specific Renilla luciferase to the levels the Firefly luciferase. For the expression of miR-26a, DF-1 cells (0.5 × 106 in each well) of 6-well plate were transfected with 2 μg of the expression constructs. For silencing miR-26a expression, 5 nM of anti-gga-miR-26a or Cy-3-labelled control anti-miRNA were transfected into DF-1, and analysed by Northern blot 48 hours later.
Analysis of IL-2 expression
Approximately 2 μg each of the purified DNA of the IL-2 expression vectors were transfected into each well of DF-1 cells in a 6-well plate and cell lysates collected 48 hours later for western blot analysis. For functional analysis of miR-26a-mediated silencing, IL-2 (500 ng) and miR-26a (2 μg) expression vectors were co-transfected into DF-1 cells. In addition, DF-1 cells co-transfected with 5 nM each of anti-gga-miR-26a or Cy-3 labelled control anti-miRNA (Ambion) with miR-26a expression or control vectors were also used in these studies.
For western blot analysis, cells lysates in protein gel sample buffer (8 M urea, 2% sodium dodecyl sulfate, 10 mM Tris-HCl [pH 6.8], 0.05% bromophenol blue) and separated on a NuPAGE 4-12% bis-Tris gel (Invitrogen) and transferred onto nitrocellulose membranes using an iBlot gel transfer system (Invitrogen). Specific detection of IL-2 was carried out using mouse HA.11 monoclonal antibody (Covance) and rabbit anti-mouse IgG peroxidase conjugate (Dako). The alpha-tubulin levels detected with the specific monoclonal antibody was used as the loading control. Membranes were developed with an ECL Western blotting system (Amersham) and images quantified using ImageQuant 300 software (GE Healthcare).
We are grateful to Mick Watson, Head of Bioinformatics at the Institute for Animal Health for technical assistance and Mick Gill for digital imaging. This work was partly funded by the Biotechnology & Biological Sciences Research Council (BBSRC), United Kingdom.
- Croce CM: Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009, 10: 704-14. 10.1038/nrg2634.PubMed CentralView ArticlePubMedGoogle Scholar
- Calnek BW: Marek's disease: a model for herpesvirus oncology. CRC Crit Rev Microbiol. 1986, 12: 293-320. 10.3109/10408418509104432.View ArticleGoogle Scholar
- Yao Y, Zhao Y, Smith LP, Lawrie CH, Saunders NJ, Watson M, Nair V: Differential expression of microRNAs in Marek's disease virus-transformed T-lymphoma cell lines. J Gen Virol. 2009, 90: 1551-9. 10.1099/vir.0.009902-0.View ArticlePubMedGoogle Scholar
- Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, Dang CV, Thomas-Tikhonenko A, Mendell JT: Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 2008, 40: 43-50. 10.1038/ng.2007.30.PubMed CentralView ArticlePubMedGoogle Scholar
- Kota J, Chivukula RR, O'Donnell KA, Wentzel EA, Montgomery CL, Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR, Mendell JR, Mendell JT: Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell. 2009, 137: 1005-17. 10.1016/j.cell.2009.04.021.PubMed CentralView ArticlePubMedGoogle Scholar
- Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V, Borbone E, Liu CG, Petrocca F, Troncone G, Calin GA, Scarpa A, Colato C, Tallini G, Santoro M, Croce CM, Fusco A: Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene. 2007, 26: 7590-5. 10.1038/sj.onc.1210564.View ArticlePubMedGoogle Scholar
- Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, Arking DE, Beer MA, Maitra A, Mendell JT: Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007, 26: 745-52. 10.1016/j.molcel.2007.05.010.PubMed CentralView ArticlePubMedGoogle Scholar
- Huse JT, Brennan C, Hambardzumyan D, Wee B, Pena J, Rouhanifard SH, Sohn-Lee C, le Sage C, Agami R, Tuschl T, Holland EC: The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes Dev. 2009, 23: 1327-37. 10.1101/gad.1777409.PubMed CentralView ArticlePubMedGoogle Scholar
- Sander S, Bullinger L, Klapproth K, Fiedler K, Kestler HA, Barth TF, Moller P, Stilgenbauer S, Pollack JR, Wirth T: MYC stimulates EZH2 expression by repression of its negative regulator miR-26a. Blood. 2008, 112: 4202-12. 10.1182/blood-2008-03-147645.View ArticlePubMedGoogle Scholar
- Gesbert F, Delespine-Carmagnat M, Bertoglio J: Recent advances in the understanding of interleukin-2 signal transduction. J Clin Immunol. 1998, 18: 307-20. 10.1023/A:1023223614407.View ArticlePubMedGoogle Scholar
- Kaiser P, Underwood G, Davison F: Differential cytokine responses following Marek's disease virus infection of chickens differing in resistance to Marek's disease. J Virol. 2003, 77: 762-8. 10.1128/JVI.77.1.762-768.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Stepaniak JA, Shuster JE, Hu W, Sundick RS: Production and in vitro characterization of recombinant chicken interleukin-2. J Interferon Cytokine Res. 1999, 19: 515-26. 10.1089/107999099313965.View ArticlePubMedGoogle Scholar
- Rothenberg EV, Ward SB: A dynamic assembly of diverse transcription factors integrates activation and cell-type information for interleukin 2 gene regulation. Proc Natl Acad Sci USA. 1996, 93: 9358-65. 10.1073/pnas.93.18.9358.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang J, Lee S, Teh CE, Bunting K, Ma L, Shannon MF: The transcription repressor, ZEB1, cooperates with CtBP2 and HDAC1 to suppress IL-2 gene activation in T cells. Int Immunol. 2009, 21: 227-35. 10.1093/intimm/dxn143.View ArticlePubMedGoogle Scholar
- Petrocca F, Lieberman J: Micromanagers of immune cell fate and function. Adv Immunol. 2009, 102: 227-44. full_text.View ArticlePubMedGoogle Scholar
- Xiao C, Rajewsky K: MicroRNA control in the immune system: basic principles. Cell. 2009, 136: 26-36. 10.1016/j.cell.2008.12.027.View ArticlePubMedGoogle Scholar
- Asirvatham AJ, Magner WJ, Tomasi TB: miRNA regulation of cytokine genes. Cytokine. 2009, 45: 58-69. 10.1016/j.cyto.2008.11.010.PubMed CentralView ArticlePubMedGoogle Scholar
- Curtale G, Citarella F, Carissimi C, Goldoni M, Carucci N, Fulci V, Franceschini D, Meloni F, Barnaba V, Macino G: An emerging player in the adaptive immune response: microRNA-146a is a modulator of IL-2 expression and AICD in T lymphocytes. Blood. 2010, 115: 265-73. 10.1182/blood-2009-06-225987.View ArticlePubMedGoogle Scholar
- Bandres E, Bitarte N, Arias F, Agorreta J, Fortes P, Agirre X, Zarate R, Diaz-Gonzalez JA, Ramirez N, Sola JJ, Jimenez P, Rodriguez J, Garcia-Foncillas J: microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin Cancer Res. 2009, 15: 2281-90. 10.1158/1078-0432.CCR-08-1818.View ArticlePubMedGoogle Scholar
- Motoyama K, Inoue H, Takatsuno Y, Tanaka F, Mimori K, Uetake H, Sugihara K, Mori M: Over- and under-expressed microRNAs in human colorectal cancer. Int J Oncol. 2009, 34: 1069-75.PubMedGoogle Scholar
- Sun R, Fu X, Li Y, Xie Y, Mao Y: Global gene expression analysis reveals reduced abundance of putative microRNA targets in human prostate tumours. BMC Genomics. 2009, 10: 93-10.1186/1471-2164-10-93.PubMed CentralView ArticlePubMedGoogle Scholar
- Childs G, Fazzari M, Kung G, Kawachi N, Brandwein-Gensler M, McLemore M, Chen Q, Burk RD, Smith RV, Prystowsky MB, Belbin TJ, Schlecht NF: Low-level expression of microRNAs let-7d and miR-205 are prognostic markers of head and neck squamous cellcarcinoma. Am J Pathol. 2009, 174: 736-45. 10.2353/ajpath.2009.080731.PubMed CentralView ArticlePubMedGoogle Scholar
- Ura S, Honda M, Yamashita T, Ueda T, Takatori H, Nishino R, Sunakozaka H, Sakai Y, Horimoto K, Kaneko S: Differential microRNA expression between hepatitis B and hepatitis C leading disease progression to hepatocellular carcinoma. Hepatology. 2009, 49: 1098-112. 10.1002/hep.22749.View ArticlePubMedGoogle Scholar
- Zhao JJ, Yang J, Lin J, Yao N, Zhu Y, Zheng J, Xu J, Cheng JQ, Lin JY, Ma X: Identification of miRNAs associated with tumorigenesis of retinoblastoma by miRNA microarray analysis. Childs Nerv Syst. 2009, 25: 13-20. 10.1007/s00381-008-0701-x.View ArticlePubMedGoogle Scholar
- Huang YS, Dai Y, Yu XF, Bao SY, Yin YB, Tang M, Hu CX: Microarray analysis of microRNA expression in hepatocellular carcinoma and non-tumorous tissues without viral hepatitis. J Gastroenterol Hepatol. 2008, 23: 87-94. 10.1111/j.1440-1746.2008.05488.x.View ArticlePubMedGoogle Scholar
- Luzi E, Marini F, Sala SC, Tognarini I, Galli G, Brandi ML: Osteogenic differentiation of human adipose tissue-derived stem cells is modulated by the miR-26a targeting of the SMAD1 transcription factor. J Bone Miner Res. 2008, 23: 287-95. 10.1359/jbmr.071011.View ArticlePubMedGoogle Scholar
- Rossi JJ: New hope for a microRNA therapy for liver cancer. Cell. 2009, 137: 990-2. 10.1016/j.cell.2009.05.038.View ArticlePubMedGoogle Scholar
- Rochman Y, Spolski R, Leonard WJ: New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol. 2009, 9: 480-90. 10.1038/nri2580.PubMed CentralView ArticlePubMedGoogle Scholar
- Levy AM, Izumiya Y, Brunovskis P, Xia L, Parcells MS, Reddy SM, Lee L, Chen HW, Kung HJ: Characterization of the chromosomal binding sites and dimerization partners of the viral oncoprotein Meq in Marek's disease virus-transformed T cells. J Virol. 2003, 77: 12841-51. 10.1128/JVI.77.23.12841-12851.2003.PubMed CentralView ArticlePubMedGoogle Scholar
- Dews M, Homayouni A, Yu D, Murphy D, Sevignani C, Wentzel E, Furth EE, Lee WM, Enders GH, Mendell JT, Thomas-Tikhonenko A: Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet. 2006, 38: 1060-5. 10.1038/ng1855.PubMed CentralView ArticlePubMedGoogle Scholar
- Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY: MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 2007, 67: 8433-8. 10.1158/0008-5472.CAN-07-1585.View ArticlePubMedGoogle Scholar
- Nair V, Kung HJ: Marek's disease virus oncogenicity: Molecular mechanisms. Marek's disease, an evolving problem. Edited by: Davison F, Nair V. 2004, Elsevier Academic Press, Oxford, 32-48. full_text.View ArticleGoogle Scholar
- Lawrie CH, Saunders NJ, Soneji S, Palazzo S, Dunlop HM, Cooper CD, Brown PJ, Troussard X, Mossafa H, Enver T, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS: MicroRNA expression in lymphocyte development and malignancy. Leukemia. 2008, 22: 1440-6. 10.1038/sj.leu.2405083.View ArticlePubMedGoogle Scholar
- Yao Y, Zhao Y, Smith LP, Watson M, Nair V: Novel microRNAs (miRNAs) encoded by herpesvirus of Turkeys: evidence of miRNA evolution by duplication. J Virol. 2009, 83: 6969-73. 10.1128/JVI.00322-09.PubMed CentralView ArticlePubMedGoogle Scholar
- Himly M, Foster DN, Bottoli I, Iacovoni JS, Vogt PK: The DF-1 chicken fibroblast cell line: transformation induced by diverse oncogenes and cell death resulting from infection by avian leukosis viruses. Virology. 1998, 248: 295-304. 10.1006/viro.1998.9290.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.